MONTREAL--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...

Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...

Abbott issued a medical device correction for some of its glucose sensors after internal testing found that some sensors may provide false low glucose readings. Hundreds of adverse events and seven ...

The second College Football Playoff rankings of the 2025 season, released on Tuesday night, provided the most recent glimpse into which Group of Five squad would make the bracket. As things stood, USF ...

RECALL ALERT: There are 5 recalls on this vehicle. Learn More. There are 5 recalls on this vehicle. Learn More. RECALL ALERT: There are 5 recalls on this vehicle. Learn More. There are 5 recalls on ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class ...

RECALL ALERT: There are 7 recalls on this vehicle. Learn More. There are 7 recalls on this vehicle. Learn More. RECALL ALERT: There are 7 recalls on this vehicle ...